High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Published:2014-07 Issue:8 Volume:15 Page:874-885
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cook Gordon,Williams Cathy,Brown Julia M,Cairns David A,Cavenagh Jamie,Snowden John A,Ashcroft A John,Fletcher Marie,Parrish Chris,Yong Kwee,Cavet Jim,Hunter Hanna,Bird Jenny M,Chalmers Anna,O'Connor Sheila,Drayson Mark T,Morris Treen C M

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;N Engl J Med,1996

2. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

3. Guidelines for the diagnosis and management of multiple myeloma 2011;Bird;Br J Haematol,2011

4. European perspective on multiple myeloma treatment strategies: update following recent congresses;Ludwig;Oncologist,2012

5. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies;Moreau;J Clin Oncol,2011

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continued need for autologous transplantation in relapsed myeloma;The Lancet Haematology;2024-09

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study;HemaSphere;2024-07-29

4. Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group;Cancers;2024-07-19

5. Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma;European Journal of Haematology;2024-06-18